Skip to main content Help with accessibility Skip to main navigation

Baricitinib

Indication

For treating moderate to severe atopic dermatitis (NICE TA681)

MHRA Drug Safety Update, 26 April 2023

JAK Inhibitors MHRA Drug Safety Update

Red

Brand:

Nice TA:

681

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:
Skin

Background

1.1 Baricitinib is recommended as an option for treating moderate to severe atopic dermatitis in adults, only if:

  • the disease has not responded to at least 1 systemic immunosuppressant, such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil, or these are not suitable, and

  • the company provides it according to the commercial arrangement

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

BwD
BP
CSR
EL
FW
GP
MB
WL
Red
Red
Red
Red
Red
Red
Red
Red
What do the colours mean?

Last Updated: 08 - Apr - 2021